In phase III trial, Libtayo demonstrates improved OS in advanced cervical cancer

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

In a phase III trial, Libtayo (cemiplimab) demonstrated a significant improvement in overall survival in women with advanced cervical cancer after progression on chemotherapy, reducing the risk of death by 31% compared to chemotherapy in the overall population. 

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe
Table of Contents

YOU MAY BE INTERESTED IN

The European Society For Medical Oncology has formally weighed in on a question that U.S. medical groups have been chipping away at as well: How can we guarantee safe and effective use of artificial intelligence in oncology?

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login